Maze Therapeutics
MAZE
94 hedge funds and large institutions have $1.11B invested in Maze Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 15 reducing their positions, and 3 closing their positions.
667% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 3
160% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 15
134% more capital invested
Capital invested by funds: $477M → $1.11B (+$638M)
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
25% more funds holding
Funds holding: 75 → 94 (+19)
9.32% more ownership
Funds ownership: 88.67% → 97.99% (+9.3%)
99% less call options, than puts
Call options by funds: $10K | Put options by funds: $778K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$20.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12.8M |
| 4 |
BlackRock
New York
|
+$11.8M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$26.8M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$14.1M |
| 3 |
Janus Henderson Group
London,
|
-$11M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$9.2M |
| 5 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$4.37M |
MAZE Hedge Fund Activity: Q3 2025 in Review
94 of the 7,642 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q3 2025, worth a combined $1.11B — up 134% from $477M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MAZE positions and 3 closed out — a net gain of 20 holders — while 39 added to existing stakes and 15 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $20.8M. The largest seller was Foresite Capital Management IV, cutting an estimated $26.8M.
- 94 institutional investors held Maze Therapeutics (MAZE) as of Q3 2025, up from 75 in Q2 2025.
- Funds reported $1.11B of Maze Therapeutics stock for Q3 2025, up 134% quarter-over-quarter.
- 23 funds opened new Maze Therapeutics positions in Q3 2025 and 3 closed out, a net change of +20 holders.
- The largest Maze Therapeutics buyer in Q3 2025 was VR Adviser, an estimated $20.8M added.
- The largest Maze Therapeutics seller in Q3 2025 was Foresite Capital Management IV, an estimated $26.8M sold.
Based on aggregated 13F filings for Q3 2025.